Biogen Idec, Swedish Orphan Biovitrum dose first patient in A-LONG Phase 2/3 study
rFVIIIFc is a fully-recombinant clotting factor developed using Biogen Idec‘s novel and proprietary monomeric Fc fusion technology. The technology makes use of a natural mechanism that recycles rFVIIIFc
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.